Summary
Merck & Co., Inc. reported a strong first quarter for 2020, with total sales reaching $12.1 billion, an increase of 11% year-over-year. This growth was primarily driven by significant increases in the oncology franchise, particularly from Keytruda, as well as contributions from alliance revenues for Lynparza and Lenvima. Vaccine sales, including Gardasil/Gardasil 9 and Pneumovax 23, also saw robust growth. The company's pharmaceutical segment profit increased by 14%, reflecting higher sales and improved cost management, partly aided by early impacts of the COVID-19 pandemic on operating expenses. Despite the overall positive performance, Merck anticipates challenges due to the COVID-19 pandemic, forecasting an unfavorable revenue impact of approximately $2.1 billion for the full year 2020. Physician-administered products, vaccines, and Keytruda are expected to be particularly affected by reduced healthcare access. In response to the uncertain environment, Merck has temporarily suspended its share repurchase program while maintaining its commitment to R&D investment and dividends. The acquisition of ArQule, Inc. for $2.7 billion in January 2020 strengthens the oncology pipeline, adding the BTK inhibitor MK-1026.
Financial Highlights
52 data points| Revenue | $12.06B |
| Cost of Revenue | $3.31B |
| Gross Profit | $8.74B |
| R&D Expenses | $2.21B |
| SG&A Expenses | $2.56B |
| Interest Expense | $212.00M |
| Net Income | $3.22B |
| EPS (Basic) | $1.27 |
| EPS (Diluted) | $1.26 |
| Shares Outstanding (Basic) | 2.53B |
| Shares Outstanding (Diluted) | 2.55B |
Key Highlights
- 1Total sales grew 11% to $12.1 billion in Q1 2020, driven by strong performance in oncology and vaccines.
- 2Keytruda sales surged 45% to $3.3 billion, highlighting its continued market leadership.
- 3Alliance revenue from Lynparza and Lenvima saw substantial increases of 84% and 72%, respectively.
- 4The company acquired ArQule, Inc. for $2.7 billion to enhance its oncology pipeline with the BTK inhibitor MK-1026.
- 5Merck anticipates a full-year revenue impact of approximately $2.1 billion due to the COVID-19 pandemic, with a focus on managing supply chains and R&D.
- 6Research and Development expenses increased by 14% to $2.2 billion, reflecting continued investment in clinical development and early-stage research.
- 7The company temporarily suspended its share repurchase program due to the COVID-19 pandemic and the current operating environment.